#AS­CO21: Mer­ck tacks on ar­mor in ear­ly-line can­cer fight with 2 Keytru­da wins set­ting the tone

With more and more PD-(L)1 check­point in­hibitors flood­ing the mar­ket, there has been a long-run­ning war over which of those drugs can se­cure a lead in ear­ly-line pa­tients. With Keytru­da on top of the world, Mer­ck is well-po­si­tioned to take the lead — and it’s rolling out a pair of stud­ies tar­get­ed di­rect­ly at that front.

As part of a broad plan of at­tack to bring I-O won­der drug Keytru­da in­to ear­li­er lines of metasta­t­ic can­cer, Mer­ck will un­veil win­ning re­sults at this year’s AS­CO from Phase II and Phase III tests as part of com­bi­na­tion ther­a­pies top­ping stan­dard of care in non-small cell lung and gas­tric can­cers.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters